Common Drugs May Prevent Antibiotic-Induced Deafness

October 06, 1997

ANN ARBOR---University of Michigan scientists have found that iron chelators---medications used to "soak up" excess iron in the bloodstream---can prevent deafness in guinea pigs exposed to antibiotics that damage delicate hair cells in the inner ear.

If clinical trials show that iron chelators work as well in humans as they do in guinea pigs, the U-M research could lead to a safe and inexpensive way to eliminate the threat of deafness to individuals treated with a common class of broad-spectrum antibiotics called aminoglycosides.

Discovered in the 1940s, these antibiotics---which include streptomycin, gentamicin, neomycin and others---are the most widely used antibiotics in the world. Because they are so effective and rarely produce allergic reactions, physicians continue to prescribe them, even though they are known to cause hearing loss and kidney damage in a significant percentage of individuals who take them.

"In the United States, aminoglycosides are most often used for emergency treatment of people with serious infections who have not responded to other types of antibiotics," said Jochen Schacht, a professor of biological chemistry and otolaryngology in the U-M Medical School. "Increasing levels of antibiotic-resistant infections associated with AIDS and a worldwide resurgence of tuberculosis, however, make it likely that their use will increase in the future.

"These drugs are a particularly serious problem in developing countries, especially China and Southeast Asia, where they are inexpensive and widely available without a prescription," Schacht added. "Mothers take children with upper respiratory infections to their local pharmacy for an injection. As a result, studies of deaf-mutism in southeastern China showed that two-thirds of the cases were caused by aminoglycosides."

The fact that aminoglycosides have toxic side-effects has been well-known since the 1940s, but only recently---thanks to 20 years of research by Schacht and colleagues at the U-M and other universities---have scientists figured out how these drugs do their damage.

In 1995, Schacht and his colleagues discovered that gentamicin is not toxic until it combines with iron in the bloodstream and becomes "activated." As these gentamicin-iron molecules form, they trigger production of free radicals---unstable molecules that rip apart and damage cells. Thousands of tiny hair cells in the inner ear are especially vulnerable. Without functional hair cells, the inner ear is unable to detect sounds or transmit signals to auditory neurons leading to the brain. The result is irreversible hearing loss.

"The solution was to avoid the formation of free radicals by preventing the gentamicin from binding with iron in the first place," Schacht said. "That's when we decided to try using iron chelators to absorb the iron and keep it from combining with gentamicin."

In an article published in the July 1997 issue of the Journal of Pharmacology and Experimental Therapeutics, Schacht published the results of experiments showing that iron chelators did protect guinea pigs from gentamicin's ototoxic effects. In this study, one group of guinea pigs received gentamicin by injection. In addition to gentamicin, another group of animals also received injections of two iron chelators---deferoxamine (DFO) and 2,3-dihydroxybenzoate (DHB). One group of animals also received the antioxidant mannitol. All animals received hearing tests before, during and after treatment. The quantity and physical condition of hair cells in the cochlea or inner ear of all animals were examined in tests conducted at the experiment's conclusion.

While the guinea pigs receiving gentamicin alone experienced significant hearing loss with complete loss of hair cells in certain areas of the cochlea, animals receiving some combination of iron chelators and antioxidant therapy did much better. "The most striking result was achieved with co-injection of gentamicin with DHB and mannitol," Schacht reported. "This regimen yielded complete protection at all measured frequencies in all animals."

Equally important, the treatment did not compromise the therapeutic effects of gentamicin. Schacht found that iron chelators and mannitol did not lower blood serum levels of gentamicin nor affect its ability to kill E. coli bacteria.

"We have the principle nailed down," Schacht said. "Now we must work with pharmaceutical firms to identify the most effective iron chelators and antioxidants available, determine a safe human dosage regimen, and then see if they will prevent hearing loss in people."

Since iron chelators and antioxidants are already approved for clinical use, Schacht said human clinical trials could start "tomorrow." He added that he already has laboratories in China and Thailand, where the problem is most prevalent, which have agreed to conduct the trials, if Schacht can obtain funding.

The research was funded by the National Institute on Deafness and Other Communication Disorders, National Institutes of Health. Co-investigators on the most recent experiment include Ben-Bo Song, U-M research fellow, and David J. Anderson, U-M professor of electrical and computer engineering. The experiments were conducted at the U-M's Kresge Hearing Research Institute.

# # # # # #





EDITORS: A copy of the U-M paper published in the 1997 Journal of Pharmacology and Experimental Therapeutics is available on request.

University of Michigan

Related Antibiotics Articles from Brightsurf:

Insights in the search for new antibiotics
A collaborative research team from the University of Oklahoma, the Memorial Sloan Kettering Cancer Center and Merck & Co. published an opinion article in the journal, Nature Chemical Biology, that addresses the gap in the discovery of new antibiotics.

New tricks for old antibiotics
The study published in the journal Immunity reveals that tetracyclines (broad spectre antibiotics), by partially inhibiting cell mitochondria activity, induce a compensatory response on the organism that decreases tissue damage caused during infection.

Benefits, risks seen with antibiotics-first for appendicitis
Antibiotics are a good choice for some patients with appendicitis but not all, according to study results published today in the New England Journal of Medicine.

How antibiotics interact
Understanding bottleneck effects in the translation of bacterial proteins can lead to a more effective combination of antibiotics / study in 'Nature Communications'

Are antivitamins the new antibiotics?
Antibiotics are among the most important discoveries of modern medicine and have saved millions of lives since the discovery of penicillin almost 100 years ago.

Hygiene reduces the need for antibiotics by up to 30%
A new paper published in the American Journal of Infection Control (AJIC), finds improved everyday hygiene practices, such as hand-washing, reduces the risk of common infections by up to 50%, reducing the need for antibiotics, by up to 30%.

Antibiotics: City dwellers and children take the most
City dwellers take more antibiotics than people in rural areas; children and the elderly use them more often than middle-aged people; the use of antibiotics decreases as education increases, but only in rich countries: These are three of the more striking trends identified by researchers of the NRW Forschungskolleg ''One Health and Urban Transformation'' at the University of Bonn.

Metals could be the link to new antibiotics
Compounds containing metals could hold the key to the next generation of antibiotics to combat the growing threat of global antibiotic resistance.

Antibiotics from the sea
The team led by Prof. Christian Jogler of Friedrich Schiller University, Jena, has succeeded in cultivating several dozen marine bacteria in the laboratory -- bacteria that had previously been paid little attention.

Antibiotics not necessary for most toothaches, according to new ADA guideline
The American Dental Association (ADA) announced today a new guideline indicating that in most cases, antibiotics are not recommended for toothaches.

Read More: Antibiotics News and Antibiotics Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.